NIH awards $3.2 million to study how unique DNA circles drive deadly pediatric brain tumors


Lukas Chavez, Ph.D., has received $3.2 million from the National Institutes of Health to study how unique DNA circles found in cancer cells drive deadly pediatric brain tumors. The research aims to expose how the circular pieces of DNA contribute to therapy resistance and open new therapeutic avenues to improve the lives of people affected by these devastating diseases.

Our goal for this project is to understand more about the functional relevance of circular extrachromosomal DNA in medulloblastoma, the most common malignant pediatric brain cancer. We hope our findings will lead to a scientific revolution in how some of the most difficult-to-treat childhood brain tumors are understood and treated.”

Lukas Chavez, Ph.D., Assistant Professor at Sanford Burnham Prebys

Extrachromosomal DNA-;or ecDNA-;was discovered decades ago, but it’s only now, with advanced technology, that researchers can investigate their sequence, structure and regulation. Recent studies have shown that tumor-promoting genes are amplified on ecDNA in some of the most aggressive medulloblastoma tumors, which may contribute to therapy resistance.

The research team has assembled a multi-institutional cohort of Whole Genome Sequencing data from 468 medulloblastoma patient samples. Using novel computational methods for the detection and reconstruction of ecDNA, they will focus on ecDNA in 82 patients (18%) and investigate the link between the presence of ecDNA and significantly poorer outcomes.

“The more we learn about how ecDNA drives pediatric brain tumors-;when they form, how they grow and what it might take to stop them-;the sooner we can develop novel therapeutic approaches that are urgently needed,” adds Chavez.

Articles You May Like

DBT Decreased Suicide Attempts in Bipolar Adolescents
AIHW report provides the most recent prevalence estimates on endometriosis
World Lung Day: Tips To Keep Your Lungs Healthy
7 Causes of Cold Sweats, Plus How to Stop Them
Philip Morris considers selling stake in pharmaceuticals unit to boost health-care division

Leave a Reply

Your email address will not be published. Required fields are marked *